New Issue: HSBC prices $3.85 million trigger jump securities linked to biotech ETF

By Wendy Van Sickle

Columbus, Ohio, Dec. 6 – HSBC USA Inc. priced $3.85 million of 0% trigger jump securities due Dec. 4, 2019 linked to the iShares Nasdaq Biotechnology exchange-traded fund, according to a 424B2 filing with the Securities and Exchange Commission.

If the ETF finishes at or above its initial level, the payout at maturity will equal par of $10 plus 34.75%.

Investors will receive par if the ETF falls by up to 20% and will be fully exposed to any losses if the ETF finishes below the 80% trigger level.

HSBC Securities (USA) Inc. is the agent. Morgan Stanley Wealth Management is handling distribution.

Issuer:	HSBC USA Inc.
Issue:	Trigger jump securities
Underlying ETF:	iShares Nasdaq Biotechnology
Amount:	$3,852,510
Maturity:	Dec. 4, 2019
Coupon:	0%
Price:	Par of $10
Payout at maturity:	If ETF gains, par plus 34.75%; if ETF falls by up to trigger level, par; otherwise, full exposure to any losses
Initial index level:	$274.05
Trigger level:	$219.24, 80% of initial level
Pricing date:	Nov. 30
Settlement date:	Dec. 5
Agent:	HSBC Securities (USA) Inc.
Distribution:	Morgan Stanley Wealth Management
Fees:	2.5%
Cusip:	40435C401

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.